The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Phospholipase A2in Vascular Disease
Open accessAbstract
Secretory phospholipase A 2(PLA 2) can be proatherogenic both in the circulation and in the arterial wall. In blood plasma, PLA 2 can modify the circulating lipoproteins and so induce formation of small dense LDL particles, which are associated with increased risk for cardiovascular disease. In the arterial wall, PLA 2 can hydrolyze lipoproteins. The PLA 2-modified lipoproteins bind tightly to extracellular proteoglycans, which may lead to their enhanced retention in the arterial wall. The modified lipoproteins may also aggregate and fuse, which can lead to accumulation of their lipids within the extracellular matrix. The PLA 2-modified particles are more susceptible to further modifications by other enzymes and agents and can be taken up by macrophages, leading to accumulation of intracellular lipids. In addition, lysophospholipids and free fatty acids, the hydrolysis products of PLA 2, promote atherogenesis. Thus, these lipid mediators can be carried, either by the PLA 2-modified lipoproteins themselves or by albumin, into the arterial cells, which then undergo functional alterations. This may, in turn, lead to specific changes in the extracellular matrix, which increase the retention and accumulation of lipoproteins within the matrix. In the present article, we discuss the possible actions of PLA 2 enzymes, especially PLA 2-IIA, in the arterial wall during atherogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Napoli, C., D'Armiento, F. P., Mancini, F. P., Postiglione, A., Witztum, J. L., Palumbo, G., & Palinski, W. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119813 · Cited by 1,014
Öörni, K., Pentikäinen, M. O., Ala-Korpela, M., & Kovanen, P. T. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31964-7 · Cited by 252
Self-citationModified LDL – trigger of atherosclerosis and inflammation in the arterial intima
Pentikäinen, M. O., Öörni, K., Ala‐Korpela, M., & Kovanen, P. T. (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00655.x · Cited by 204
Self-citationVascular transcellular signaling.
Marcus, A. J., & Hajjar, D. P. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)35344-x · Cited by 114
Cited by
The immunology of atherosclerosis
Gisterå, A., & Hansson, G. K. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.51 · Cited by 982
Davidovici, B. B., Sattar, N., Jörg, P. C., Puig, L., Emery, P., Barker, J. N., van de Kerkhof, P., Ståhle, M., Nestle, F. O., Girolomoni, G., et al. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.103 · Cited by 711
Biochemistry and Physiology of Mammalian Secreted Phospholipases A2
Lambeau, G., & Gelb, M. H. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.76.062405.154007 · Cited by 513
Recent progress in phospholipase A2 research: From cells to animals to humans
Murakami, M., Taketomi, Y., Miki, Y., Sato, H., Hirabayashi, T., & Yamamoto, K. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.12.001 · Cited by 507
Biomarkers of Atherosclerotic Plaque Instability and Rupture
Koenig, W., & Khuseyinova, N. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000251503.35795.4f · Cited by 418
Metadata
- Authors
- Hurt-Camejo, E., Camejo, G., Peilot, H., Öörni, K., & Kovanen, P.
- Venue
- Circulation Research
- Published
- 2001-08-17
- Volume
- 89
- Issue
- 4
- Pages
- 298-304
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2157693395
- Cited by
- 219
- References
- 4
- FWCI
- 5.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phospholipase A2in Vascular Disease. https://app.cochat.ai/papers/10.1161/hh1601.095598
- The paper
- Hurt-Camejo, E., Camejo, G., Peilot, H., Öörni, K., & Kovanen, P. (2001). Phospholipase A2in Vascular Disease. Circulation Research. https://doi.org/10.1161/hh1601.095598
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.